Acta Scientific Gastrointestinal Disorders (ASGIS)(ISSN: 2582-1091)

Review Article Volume 5 Issue 1

Barrett's Esophagus: The Evolution of Views (Review)

NYU Kohanenko, TSH Morgoshiia, M Ter-Ovanesov, AV Glebova, OG Vavilova and AA Kashintsev*

Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State Pediatric Medical University" of the Ministry of Health of Russia, Russian Federation

*Corresponding Author: AA Kashintsev, Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State Pediatric Medical University" of the Ministry of Health of Russia, Russian Federation.

Received: November 17, 2021; Published: December 31, 2021


Barrett's esophagus (BE) is known to be a disease characterized by the replacement of the multilayer flat epithelium with a metaplastic columnar epithelium. Technological advances in endoscopic procedures have radically changed the treatment of dysplastic and early cancers from aggressive to organ-preserving endoscopic treatment. A multi-modal approach to treatment has been shown combining endoscopic resection of visible and/or protruding lesions with ablative methods for early forms of mucosal lesions in Barrett's esophagus, followed by long-term follow-up, which improves the results of treatment of this nosological form. Safe and effective endoscopic treatment can be both tissue acquisition, as in endoscopic mucosal resection with endoscopic submucous dissection, and tissue ablation, as in photodynamic therapy, radiofrequency stimulation and cryotherapy. Joint decision-making between a patient and a doctor is important when considering treatment of Barrett's esophagus and dysplasia.

Keywords: Barrett's Esophagus; Gastroesophageal Reflux Disease; Esophageal Adenocarcinoma; Endoscopy; Dysplasia Treatment; Surgical Treatment


  1. Fitzgerald RC., et al. “British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus”. Gut 63 (2014): 7-42.
  2. Birkmeyer JD., et al. “Surgical volume and operational mortality in the United States”. The New England Journal of Medicine (2003): 349:2117-2127.
  3. Konda VJ., et al. “Is the risk of developing concomitant invasive esophageal cancer overestimated in highly dispersed Barrett's esophageal dysplasia?”. Clinical Gastroenterology and Hepatology (2008): 6: 159-164.
  4. Faith m., et al. “Picture of the lymphogenic spread of of barrett's cancer”. World Journal of Surgery 27 (2003): 1052-1057.
  5. Barrett NR. “Chronic peptic ulcer of the oesophagus and 'oesophagitis'”. British Journal of Surgery 38 (1950): 175-182.
  6. Allison PR and Johnstone AS. “The oesophagus lined with gastric mucous membrane”. Thorax 8 (1953): 87-101.
  7. Barrett NR. “The lower esophagus lined by columnar epithelium”. Surgery 41 (1957): 881-894.
  8. Kandel P and Wallace MB. “The Role of Adjunct Imaging in Endoscopic Detection of Dysplasia in Barrett's Esophagus”. Gastrointestinal Endoscopy Clinics of North America 27 (2017): 423-446.
  9. Gora MJ., et al. “Tethered capsule endomicroscopy for microscopic imaging of the esophagus, stomach,and duodenum without sedation in humans (with video)”. Gastrointestinal Endoscopy 88 (2018): 830-840.
  10. Paull A., et al. “The histologic spectrum of Barrett's esophagus”. The New England Journal of Medicine 295 (1976): 476-480.
  11. Quiglet EMM. “The gastroesophageal junction revision: Perspectives in GERD”. World Gastroenterology News 2 (2000): 25-28.
  12. Hayward J. “The lower end of the esophagus”. Thorax 16 (1961): 36-41.
  13. Hamilton SR., et al. “Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction”. Human Pathology 19 (1998): 942-948.
  14. Clark GW., et al. “Is Barrett's metaplasia the source of adenocarcinoma of the cardia?”. The Archives of Surgery 129 (1994): 609-614.
  15. Hirota W., et al. “Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophago-gastric junction: prevalence and clinical data”. Gastroenterology 116 (1999): 277-285.
  16. Stein HJ., et al. “Esophageal cancer: Screening and surveillance”. Diseases of the Esophagus 1 (1996): 3-19.
  17. Reid BJ., et al. “Flow cytometric and histologic progression to malignancy in Barrett's esophagus prospective endoscopic surveillance of a cohort”. Gastroenterology 102 (1992): 1212-1219.
  18. Schnell TG., et al. “Adenocarcinoma arising in tongues or short segments of Barrett's esophagus”. Digestive Diseases and Sciences 37 (1992): 137-143.
  19. Konda VJA and Souza RF. “Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice”. Digestive Diseases and Sciences 63 (2018): 2070-2080.
  20. Vakil N., et al. “The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus”. The American Journal of Gastroenterology 8 (2006): 1900-1920.
  21. Ter-Ovanesov MD. “Factors of prognosis of surgical treatment of cancer of the proximal part of the stomach. Abstract of the dis”. Doctor of Medical Sciences Mosco (2007): 52.
  22. Spechler S., et al. “American Gastroenterological Association Medical Position Statement on the Management of Barrett’s Esophagus”. Gastroenterology 140 (2011): 1084-1091.
  23. ASGE Technology Committee. Thosani N., et al. “ASGE Technology Committee systematic review and meta-analysis assessing the ASGE Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for adopting real-timeimaging-assisted endoscopic targeted biopsy during endoscopic surveillance of Barrett's esophagus”. Gastrointestinal Endoscopy 83 (2016): 684-698.
  24. Hvid-Jensen F., et al. “Incidence of adenocarcinomaamong patients with Barrett's esophagus”. The New England Journal of Medicine 365 (2011): 1375-1383.
  25. Bremner CG. “Barrett's esophagus”. In DeMeester T.R., Matthews H.R. (eds): International Trends in General Thoracic Surgery. Benign Esophageal Diseases. St. Louis, CV Mosby. 3 (1987): 227-244.
  26. Cameron AJ., et al. “Adenocarcinoma of the esophago-gastric junction and Barrett's esophagus”. Gastroenterology 109 (1995): 1541-1546.
  27. Tytgat GNJ. “What are the endoscopic criteria for diagnosing columnar metaplasia?”. In Guili R., Tytgat G.N.J. DeMeester T.R., Galmiche J.P. (eds): The Esophageal Mucosa. Amsterdam, Elsevier (1994): 795-798.
  28. Phoa KN., et al. “Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentrestudy (EURO-II)”. Gut (2016): 65 (4): 555-562.
  29. Weusten B., et al. “Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement”. Endoscopy2 (2017): 191-198.
  30. Barret M., et al. “Single-session endoscopic resection and focal radiofrequency ablation for short-segment Barrett’s esophaguswith early neoplasia”. Gastrointestinal Endoscopy1 (2016): 29-36.
  31. di Pietro M and Fitzgerald R. “Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia”. Gut2 (2017): 392-393.
  32. Shaheen NJ., et al. “ACG clinical guideline: diagnosis and management of Barrett’s esophagus”. The American Journal of Gastroenterology 1 (2016): 30-50.
  33. Brown J., et al. “Effectiveness of focal vs. balloon radiofrequency ablation devices in the treatment of Barrett’s esophagus”. United European Gastroenterology Journal 2 (2015): 236-241.
  34. Hvid-Jensen F., et al. “Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients”. Alimentary Pharmacology and Therapeutics9 (2014): 984-991.
  35. Singh S., et al. “Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis”. Gut8 (2014): 1229-1237.
  36. Kuipers EJ., et al. “Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fun-doplication”. The New England Journal of Medicine 334 (1996): 1018-1022.
  37. Clermont M and Falk G. “Clinical Guidelines Update on the Diagnosis and Management of Barrett’s Esophagus”. Digestive Diseases and Sciences 8 (2018): 2122-2128.
  38. Ortiz A., et al. “Conservative treatment versus antireflux surgery in Barrett's esophagus: Long-term results of a prospective study”. British Journal of Surgery 83 (1996): 276-278.
  39. Ye W., et al. “Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery”. Gastroenterology 121 (2001): 1286-1293.
  40. McDonald ML., et al. “Barrett's esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance?”. The Journal of Thoracic and Cardiovascular Surgery 111 (1996): 1135-1140.
  41. Spechler SJ. “Barrett's Esophagus”. The New England Journal of Medicine11 (2002): 836-842.
  42. Morgoshiia TSh. “Comparative evaluation of surgical interventions in cancer of the distal stomach”. Bulletin of Surgery2 (2006): 20-22.
  43. Pouw RE., et al. “Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia”. Clinical Gastroenterology and Hepatology 8 (2010): 23-29.
  44. Enzinger PC and Mayer RJ. “Esophageal cancer”. The New England Journal of Medicine 349 (2003): 2241-2252.
  45. Pennathur A and Luketich JD. “Resection for esophageal cancer: strategies for optimal management”. The Annals of Thoracic Surgery 85 (2014): S751-S756.
  46. Low DE., et al. “Guidelines for perioperative cara in esophagectomy: Enhanced recovery after surgery (ERAS) Society recommendations”. World Journal of Surgery 43 (2019): 299-330.
  47. Klevebro F., et al. “Application of standardized hemodynamic protocols within enhanced recovery after surgery programs to improve outcomes associated with anastomotic leak and conduit necrosis in patients undergoing esophagectomy”. Journal of Thoracic Disease 11 (2019): 692-701.
  48. Rizk NP., et al. “Optimum lymphadenectomy for esophageal cancer”. Annals of Surgery 251 (2012).
  49. Zayac A and Almhanna K. “Esophageal, gastric cancer and immunotherapy: small steps in the right direction?”. Translational Gastroenterology and Hepatology 5 (2020): 9.
  50. Woodley FW., et al. “Gastroesophageal reflux in cystic fibrosis across the age spectrum”. Translational Gastroenterology and Hepatology 4 (2019): 69.


Citation: AA Kashintsev., et al. “Barrett's Esophagus: The Evolution of Views (Review)". Acta Scientific Gastrointestinal Disorders 5.1 (2022): 74-84.


Copyright: © 2022 AA Kashintsev., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US